# A Phase III Study Comparing the Weight Loss Effects of Semaglutide Injection and Wegovy®

> **NCT06633783** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Hangzhou Jiuyuan Gene Engineering Co. Ltd.,** · enrollment: 370 (estimated)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** Semaglutide
- **DRUG:** Semaglutide

## Key facts

- **NCT ID:** NCT06633783
- **Lead sponsor:** Hangzhou Jiuyuan Gene Engineering Co. Ltd.,
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-10-30
- **Primary completion:** 2026-05-30
- **Final completion:** 2026-10-30
- **Target enrollment:** 370 (ESTIMATED)
- **Last updated:** 2024-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06633783

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06633783, "A Phase III Study Comparing the Weight Loss Effects of Semaglutide Injection and Wegovy®". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06633783. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*